SCHEMBL15312837

SCHEMBL15312837

COc1ccc2[c]cc(-c3csc(NC(C)C)n3)nc2c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 1/20 0.38
MEN1 O00255 8/20 0.37
KMT2A Q03164 8/20 0.37
POLB P06746 1/20 0.37
ALOX5 P09917 4/20 0.37
ALDH1A1 P00352 5/20 0.34
KDM4E B2RXH2 3/20 0.34
RAB9A P51151 5/20 0.34
NPC1 O15118 3/20 0.34
MAPT P10636 3/20 0.33
ALOX15 P16050 2/20 0.33
MAPK1 P28482 2/20 0.33
HSD17B10 Q99714 1/20 0.33
LMNA P02545 3/20 0.33
HPGD P15428 1/20 0.33
KDM1A O60341 1/20 0.33
USP2 O75604 1/20 0.32
TP53 P04637 1/20 0.32
OPRK1 P41145 1/20 0.32
CASP3 P42574 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL577705 0.83 ALDH1A1 (0.36) MEN1KMT2APOLBALOX5ALDH1A1
SCHEMBL8146846 0.80 TYR (0.42) TYRMEN1KMT2APOLBALOX5
SCHEMBL577373 0.78 ALDH1A1 (0.35) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL693184 0.77 TYR (0.47) TYRMEN1KMT2APOLBALOX5
SCHEMBL10220218 0.76 TYR (0.38) TYRMEN1KMT2APOLBALOX5
SCHEMBL577515 0.76 KDM4E (0.33) ALDH1A1KDM4ERAB9ANPC1MAPT
SCHEMBL12732038 0.75 ABCC1 (0.38) TYRMEN1KMT2APOLBALOX5
SCHEMBL578194 0.74 PDE10A (0.36) POLBALDH1A1KDM4ERAB9ANPC1
SCHEMBL577561 0.72 ALDH1A1 (0.38) MEN1KMT2AALDH1A1KDM4ERAB9A
SCHEMBL27787206 0.72 TYR (0.44) TYRMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130273005-A1 METHODS FOR TREATING HCV GILEAD SCIENCES, INC. (US) 2013-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130273005-A1 METHODS FOR TREATING HCV HAVCR2, HCCS, LIPC TYR 2425/4885MEN1 4840/4885KMT2A 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.